Quick immune boost before breast cancer surgery: does it work?
NCT ID NCT05180006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could increase immune cell activity in early-stage breast cancer. It involved 33 patients with triple-negative or HER2-positive breast cancer. The trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab (with or without bevacizumab, trastuzumab, or pertuzumab)
- What this could lead to
- If successful, this could show that a short course of immunotherapy before standard treatment helps the immune system fight breast cancer more effectively.
- What could go wrong
- This was a small, early-phase trial that was terminated, so results are limited. The study focused on immune cell changes, not direct patient outcomes like survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy
Villejuif, 94800, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?